Table 1.
Comparison/consensus intervals for select hematology and biochemistry assays for US, Africa, and Protocols IAVI 010 and V001.
Figure 1.
Disposition, by gender, of participants screened in two HIV vaccine clinical trials conducted in Nairobi.
Table 2.
Reasons for ineligibility in two HIV vaccine clinical trials in Nairobi.
Table 3.
Ineligibility due to abnormal hematology and biochemistry values in two HIV vaccine clinical trials.
Table 4.
Participants with selected laboratory abnormalities: those who would have qualified using East/South Africa consensus intervals.